StayinFront, Inc signs two year global partnership agreement with eyeforpharma

July 21, 2009, London

eyeforpharma has signed a two year partnership agreement with StayinFront Inc. a global provider of enterprise-wide life sciences CRM and SFA solutions. StayinFront will be partnering with eyeforpharma worldwide on conferences, webinars, seminars and newsletters on topics ranging from CRM and Sales Force Effectiveness to eMarketing, Electronic Territory Mapping System and Key Account Management. There will also be a major online and electronic presence supporting this strategic relationship. Paul Simms the Managing Director of eyeforpharma stated that "eyeforpharma has worked closely with StayinFront for a number of years. This partnership is a natural progression of our close global relationship. I look forward to collaborating and reaching our mutual goals and objectives."

Martin Hensen, head of e-strategies, UCB Germany: Making e-marketing more than just an add-on

July 31, 2009, London

With the vast majority of our marketing efforts focused squarely on the sales force, e-marketing is still an "add on," says Martin Hensen, head of e-strategies, UCB Germany. But successful e-CRM strategies are the basic starting point for all e-activities, he told eyeforpharma.

GenericsWeb Holds Course through Economic Turmoil

Sydney, Australia 3rd August, 2009

Pharmaceutical Patent Intelligence firm GenericsWeb today announced that it had achieved in excess of 30% growth in revenue over the past financial year ending June 30th 2009, despite facing tough economic circumstances due to the global financial meltdown.

Prasugrel: a flawed approval?

On July 10, 2009, the FDA approved Effient (prasugrel) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. However, the approval has surprised many physicians as prasugrel has had a tortuous clinical development program, with important questions raised over its clinical benefits and the trial design.

How pharmaceutical and biotech industry could  survive and thrive in a world where new media technology creates our lives and our future?

Social networks may shape the future of pharmaceutical and biotechnology industry

We live in a time of mass media. The internet and computers of all shapes and sizes could soon replace the written word, television and radio. We pay our bills through internet-banking. We read newspapers on their internet sites. We make new acquaintances through virtual networks.

Drug repositioning strategies: a different approach to innovation

With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.

US market offers the greatest biosimilar rewards

With Japan poised to receive its first biosimilar and the US moving ever closer to the establishment of an approval pathway, the biosimilars market is set for imminent expansion. Given the size of the US market and the generic erosion which characterizes it, the sector is an attractive prospect for large and established pharmaceutical companies looking to succeed in the biosimilars sector.

World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.